PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15297001-1	2004	To examine the effects of olprinone, a phosphodiesterase III inhibitor, on cerebral blood flow (CBF), we compared the effects of olprinone on CBF to that of acetazolamide.	olprinone	26-35	CCAAT/enhancer binding protein zeta	Rattus norvegicus	96-99	
15297001-1	2004	To examine the effects of olprinone, a phosphodiesterase III inhibitor, on cerebral blood flow (CBF), we compared the effects of olprinone on CBF to that of acetazolamide.	olprinone	129-138	CCAAT/enhancer binding protein zeta	Rattus norvegicus	142-145	
15297001-4	2004	Resting rCBF showed a significant negative correlation with the change in rCBF (DeltaCBF) during olprinone infusion (r = -0.43, P=0.013), but no significant correlation was seen following acetazolamide administration.	olprinone	97-106	CCAAT/enhancer binding protein zeta	Rattus norvegicus	8-12	
15297001-4	2004	Resting rCBF showed a significant negative correlation with the change in rCBF (DeltaCBF) during olprinone infusion (r = -0.43, P=0.013), but no significant correlation was seen following acetazolamide administration.	olprinone	97-106	CCAAT/enhancer binding protein zeta	Rattus norvegicus	74-78	
15297001-5	2004	The difference in rCBF between the right and left cortex increased more following acetazolamide administration (14.1+/-10.9 ml/(min 100 g)) than during olprinone infusion (5.4+/-4.8 ml/(min 100 g), P=0.013).	olprinone	152-161	CCAAT/enhancer binding protein zeta	Rattus norvegicus	18-22	
15297001-7	2004	The vasodilatory effects of olprinone are dependent on resting CBF instead of on the intracerebral steal phenomenon that occurs with acetazolamide.	olprinone	28-37	CCAAT/enhancer binding protein zeta	Rattus norvegicus	63-66